ALNY

Business Context and Reporting Period

Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2009
Business Overview: Alnylam is a biopharmaceutical company developing therapeutics based on RNA interference (RNAi). The company has no approved products and relies on strategic alliances (Roche, Takeda, Novartis, Cubist) and government contracts for revenue. Key programs include ALN-RSV01 (Phase II for RSV) and ALN-VSP (Phase I for liver cancer).

Key Financial Metrics

Note: Total Cash, Equivalents & Marketable Securities calculated as Cash ($227,268) + Current Marketable Securities ($180,786) + Non-Current Marketable Securities ($96,647).

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased 13% to $25.1 million, driven primarily by the recognition of revenue from the Takeda alliance (upfront and milestone payments) and the new Cubist alliance. This offset a significant decrease in government contract revenue due to the termination of the DTRA program.
• Expense Increase: Operating expenses rose 26% to $33.0 million. Research and Development (R&D) expenses increased 25% to $25.3 million, largely due to higher license fees (primarily to Isis) and the initiation of the ALN-VSP Phase I trial. General and Administrative (G&A) expenses increased 31% to $7.7 million due to professional fees and stock-based compensation.
• Net Loss Expansion: Net loss widened significantly to $7.9 million from $1.2 million, reflecting higher operating costs and a decrease in interest income (from $4.7M to $2.0M) due to lower interest rates.
• Joint Venture Investment: The company invested an additional $10.0 million in Regulus Therapeutics Inc. in Q1 2009. The equity in loss of the joint venture was $1.5 million.

Guidance, Outlook, and Risks

Management Commentary & Outlook:

• Liquidity: Management believes existing cash, cash equivalents, and marketable securities ($504.7 million), combined with expected revenue from alliances, are sufficient to fund operations for at least the next several years.
• Revenue Recognition: Revenues are recognized on a straight-line basis over the performance period for major alliances (Roche: 5 years; Takeda: 7 years; Cubist: 7 years) as the company cannot reasonably estimate the level of effort required.
• Future Funding: The company expects to require substantial additional funds in the future to complete R&D and may seek financing through collaborations, equity, or debt offerings.

Risks and Contingencies:

• Development Risk: No RNAi therapeutics have received regulatory approval. The technology is unproven, and clinical trials may fail or be delayed.
• Collaboration Dependence: The business relies heavily on partners (Roche, Takeda, Novartis, Cubist) for funding and commercialization. Termination of these agreements would materially harm the company.
• Government Funding: The DTRA contract was terminated in early 2009, eliminating potential future funding of up to $27.7 million. The NIAID contract remains active but is subject to government appropriation.
• Intellectual Property: The company faces potential patent challenges and litigation risks inherent in the RNAi field.

Investor Verification Checklist

• Deferred Revenue Runway: Verify the amortization schedule of the $331.5 million in deferred revenue to understand the timing of future revenue recognition.
• Cash Burn Rate: Monitor the trend of operating cash flow, which turned positive ($1.2M) in Q1 2009 compared to negative ($8.7M) in Q1 2008, to assess sustainability without new financing.
• Clinical Trial Progress: Track the status of ALN-RSV01 (Phase II) and ALN-VSP (Phase I) as these are critical for future milestone payments and product commercialization.
• Regulus Joint Venture: Review the financial health and progress of Regulus Therapeutics, in which Alnylam holds a 49% interest and recognizes losses.
• License Fee Obligations: Assess the impact of the amended Isis agreement (potential $31M in fees) and other license obligations on future cash outflows.